Celsion Corporation to Hold Year-End 2021 Financial Results and Business Update Conference Call on Thursday, March 31, 2022 LAWRENCEVILLE, N.J., March 24, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines,...

Celsion Corporation Announces Pricing of $30 Million Registered Direct Offerings of Convertible Redeemable Preferred Stock LAWRENCEVILLE, N.J., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, today...

CELSION CORPORATION ANNOUNCES ADJOURNMENT OF ANNUAL MEETING 49% of Shares Voted, Quorum Not Established To Hold Annual Meeting Polls Remain Open Stockholders Holding Unvoted Proxies Are Strongly Encouraged to Vote Their Shares LAWRENCEVILLE, N.J.,...